Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Blinatumomab
Related studies linked through entity extraction aliases.
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
- Status
- RECRUITING
- Phase
- PHASE3
Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE3
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- Status
- RECRUITING
- Phase
- PHASE1
Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
PETHEMA-BLIN-01/PET069014 (BLIN-01)
- Status
- TERMINATED
- Phase
- PHASE2
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
- Status
- COMPLETED
- Phase
- PHASE3
Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Status
- COMPLETED
- Phase
- PHASE1
Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
- Status
- TERMINATED
- Phase
- PHASE2
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
- Status
- TERMINATED
- Phase
- PHASE2
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3